Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Jul 1;25(1):483.
doi: 10.1186/s12876-025-04071-y.

Diagnostic performances of adding transition and hepatobiliary phase to washout in gadoxetic acid-enhanced MRI for subcentimeter hepatocellular carcinoma

Affiliations
Comparative Study

Diagnostic performances of adding transition and hepatobiliary phase to washout in gadoxetic acid-enhanced MRI for subcentimeter hepatocellular carcinoma

Li Yang et al. BMC Gastroenterol. .

Abstract

Objective: To compare the diagnostic performances of washout (WO) criteria confined to portal venous phase (PVP), extended to transition phase (TP) or hepatobiliary phase (HBP) for subcentimeter hepatocellular carcinoma (HCC) using gadoxetic acid-enhanced MRI.

Materials and methods: Two hundred patients (mean age, 53.4 ± 10.4 years) who were scanned with 1.5-T gadoxetic acid-enhanced MRI were included. Arterial phase hyperenhancement and signal intensity on PVP, TP and HBP images were evaluated. Three WO criteria were established: WO confined to the PVP, WO extended to the TP and WO extended to the HBP.

Assessment: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy with 95% confidence interval were calculated for WO confined to the PVP and WO extended to the TP or HBP, and generalized estimating equation was used to compare sensitivity, specificity, PPV, NPV and accuracy.

Results: A total of 200 surgically confirmed subcentimeter hepatic nodules (171 HCCs and 29 non-HCCs) were included. For solitary subcentimeter HCCs, WO extended to the TP showed significantly higher sensitivity and accuracy than WO confined to the PVP (70.80% vs. 49.64%, P < 0.05; 71.52% vs. 55.70%, P < 0.001) and AFP (70.80% vs. 51.09%, P < 0.05; 71.52% vs. 55.70%, P < 0.05), but no significant difference in specificity (76.19% vs. 95.24%, P > 0.05; 76.19% vs. 85.71%, P > 0.05). Extending WO to the HBP achieved significantly higher sensitivity (78.10% vs. 49.64%, P < 0.001; 78.10% vs. 70.80%, P < 0.05) and accuracy (75.32% vs. 55.70%, P < 0.001; 75.32% vs. 71.52%, P < 0.05) compared to WO confined to the PVP and WO extended to the TP, but lower specificity (57.14%% vs. 95.24%, P < 0.05) compared to WO confined to the PVP. The combination of AFP with WO confined to the PVP, WO extended to the TP, or WO extended to the HBP yielded significantly higher sensitivities and accuracies compared to each MRI washout criterion alone (all P < 0.001).

Conclusion: WO extending to TP rather than HBP may be a preferred alternative for diagnosing subcentimeter HCC, and the supplement of AFP may improve sensitivity and accuracy.

Keywords: Gadoxetic acid; Hepatobiliary phase; Hepatocellular carcinoma; Magnetic resonance imaging; Subcentimeter; Transition phase.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This single-center retrospective study was approved by Zhongshan Hospital of Fudan University Ethics Committee (No. B2020-372R) and the committee agreed that the requirement for patient written informed consent was waived. All methods were conducted in accordance with the principles outlined in the 1964 Declaration of Helsinki and its later amendments. Consent for publication: Not applicable. Human Ethics and Consent to Participate: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the patient’s selection. HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma, cHCC-ICC, combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma; MALT, mucosa-associated lymphoid tissue
Fig. 2
Fig. 2
Subcentimeter hepatocellular carcinoma (HCC) with washout appearance in transitional and hepatobiliary phase in a 78-year-old man with chronic hepatitis B. Arterial phase (a) shows nonrim hyperenhancement (hyperintensity) of a 5 mm nodule (arrow) in hepatic segment VIII, and the nodule shows isointensity in portal venous phase (b), whereas it shows hypointensity in transitional (c) and hepatobiliary phase (d). Axial T2-weighted images (repetition time msec/echo time msec, 4087.9/106; e and f) show a 5 mm nodule in hepatic segment VIII (e) and a 40 mm lesion in hepatic segment V (f) with mild hyperintensity, and both lesions were surgically confirmed HCCs
Fig. 3
Fig. 3
Subcentimeter hepatocellular carcinoma (HCC) with washout appearance in hepatobiliary phase in a 53-year-old woman with chronic hepatitis B. Precontrast T1-weighted image shows hypointensity of a 7 mm nodule in hepatic segment VII (arrow), and the nodule shows nonrim hyperenhancement in arterial phase (b) and slight hyperintensity in portal venous (c) and transitional phase (d), whereas it shows hypointensity in hepatobiliary phase (e). Axial T2-weighted images (repetition time msec/echo time msec, 4087.9/106; f) shows mild hyperintensity of the nodule
Fig. 4
Fig. 4
A decision tree for the use of AFP as the primary gatekeeper before MRI. If AFP is elevated (≥ 20 ng/mL), washout in the transitional phase (TP) is the best trade-off between sensitivity and specificity with high positive predictive value (PPV) and accuracy. If AFP is normal (< 20 ng/mL), washout in the portal venous phase (PVP) or hepatobiliary phase (HBP) is recommended, depending on the diagnostic cut-offs used
Fig. 5
Fig. 5
Mucosa-associated lymphoid tissue lymphoma with washout appearance in portal venous phase in a 40-year-old man with chronic hepatitis B. Precontrast T1-weighted image shows hypointensity of an 8.6 mm nodule in hepatic segment V (arrow), and the nodule shows nonrim hyperenhancement in arterial phase (b) and hypointensity in portal venous (c), transitional (d) and hepatobiliary phase (e). Axial T2-weighted image (repetition time msec/echo time msec, 4087.9/106; f) shows mild hyperintensity of the nodule

Similar articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209–49. - PubMed
    1. Goutte N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country. J Hepatol. 2017;66:537–44. - PubMed
    1. Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2022;77:128–39. - PMC - PubMed
    1. Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68:526–49. - PMC - PubMed
    1. Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology (Baltimore MD). 2022;75:541–9. - PMC - PubMed

Publication types

LinkOut - more resources